NCT02683928 - To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL

GBR 830

BIOLOGICAL

Placebo

Trial Locations (17)

10029

Glenmark Investigational Site 1, New York

27612

Glenmark Investigational Site 9, Raleigh

33624

Glenmark Investigational Site 15, Tampa

45324

Glenmark Investigational Site 13, Fairborn

63117

Glenmark Investigational Site 11, St Louis

72759

Glenmark Investigational Site 14, Rogers

75230

Glenmark Investigational Site 2, Dallas

77494

Glenmark Investigational Site 17, Katy

77598

Glenmark Investigational Site 12, Webster

90045

Glenmark Investigational Site 5, Los Angeles

92123

Glenmark Investigational Site 3, San Diego

08009

Glenmark Investigational Site 16, Berlin

L3P 1X2

Glenmark Investigational Site 8, Markham

K9J 5K2

Glenmark Investigational Site 7, Peterborough

L4C 9M7

Glenmark Investigational Site 6, Richmond Hill

N2J 1C4

Glenmark Investigational Site 10, Waterloo

H2K 4L5

Glenmark Investigational Site 4, Montreal